Stronger caffeine warnings
This article was originally published in The Tan Sheet
Executive Summary
Connecticut Attorney General Richard Blumenthal says May 1 FDA and Novartis should strengthen warning labels on caffeine product NoDoz following the death of a 19-year-old male. Blumenthal urges stronger warning labels about the severe health consequences of overdosing and caffeine toxicity, saying the current warning labels for NoDoz and other pill forms of caffeine are inadequate. He also advises increasing the minimum age for buying NoDoz from 12 to 18. A study reported in January found many multi-ingredient supplements containing caffeine were most commonly tied to supplement-related adverse events (1"The Tan Sheet" Jan. 29, 2007, p. 3)...
You may also be interested in...
Multi-Ingredient Caffeine Products Easily Top Adverse Event List, Study Finds
The vast majority of adverse events that can be attributed with near certainty to a supplement involve weight-loss or energy-enhancing products, a study conducted by Christine Haller, M.D., finds
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.